[CAS NO. 1332837-31-6] Fosifloxuridine nafalbenamide
PRODUCTS SPECIFICATIONS [1332837-31-6]
DESCRIPTION [1332837-31-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 613.53 |
| Molecular Formula | C29H29FN3O9P |
| SMILES | O=P(OC[C@H]1O[C@@H](N(C=C(F)C2=O)C(N2)=O)C[C@@H]1O)(N[C@@H](C)C(OCC3=CC=CC=C3)=O)OC4=CC=CC5=C4C=CC=C5 |
Summary
Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy [1] [2] .
In Vitro
Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02723240 | University of Oxford |
Cancer
|
January 2016 | Phase 1 |
| NCT03428958 | NuCana plc |
Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal
|
October 16, 2018 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 162.99 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6299 mL | 8.1496 mL | 16.2991 mL |
| 5 mM | 0.3260 mL | 1.6299 mL | 3.2598 mL |
| 10 mM | 0.1630 mL | 0.8150 mL | 1.6299 mL |
References
- [1] Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
- [2] Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.